SCHEMBL8050443

SCHEMBL8050443

COc1cccc2c(CCNc3c(Cl)cc(Nc4ccnc5ccccc45)cc3Cl)c[nH]c12

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAK O14976 5/20 0.50
RIPK2 O43353 2/20 0.50
COQ8A Q8NI60 2/20 0.50
NLK Q9UBE8 2/20 0.50
MTNR1A P48039 1/20 0.46
MTNR1B P49286 1/20 0.46
HTR2C P28335 1/20 0.44
HTR2B P41595 1/20 0.44
HTR2A P28223 1/20 0.43
FADS1 O60427 1/20 0.43
HTT P42858 1/20 0.42
HTR6 P50406 1/20 0.42
USP2 O75604 1/20 0.40
TP53 P04637 1/20 0.40
CYP1A2 P05177 1/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2D6 P10635 1/20 0.40
ALOX15 P16050 1/20 0.40
MAPK1 P28482 1/20 0.40
CYP2C19 P33261 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8050440 0.88 FADS1 (0.45) GAKRIPK2COQ8ANLKHTR2A
SCHEMBL8045371 0.84 MTNR1A (0.49) MTNR1AMTNR1BHTR2AHTR6USP2
SCHEMBL8043495 0.83 USP2 (0.49) GAKRIPK2COQ8ANLKMTNR1A
SCHEMBL8045380 0.83 POLB (0.56) HTR2AFADS1HTR6KDR
SCHEMBL8045376 0.83 MTNR1A (0.46) MTNR1AMTNR1BHTR2AHTR6USP2
SCHEMBL13130721 0.82 MTNR1A (0.41) GAKRIPK2COQ8ANLKMTNR1A
SCHEMBL8047787 0.79 MTNR1A (0.46) GAKRIPK2COQ8ANLKMTNR1A
SCHEMBL12810898 0.77 ADRB3 (0.41) MTNR1AMTNR1BHTR2AHTR6USP2
SCHEMBL12845353 0.75 GAK (0.53) GAKRIPK2COQ8ANLKHTR2A
SCHEMBL12811052 0.73 GAK (0.41) GAKRIPK2COQ8ANLKMTNR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11583524-B2 Inhibitors of the interaction between MDM2 and P53 JANSSEN PHARMACEUTICA NV (BE) 2023-02-21 US disclosed
US-20200121667-A1 Inhibitors Of The Interaction Between MDM2 And P53 JANSSEN PHARMACEUTICA NV (BE) 2020-04-23 US disclosed
US-20170112818-A1 INHIBITORS OF THE INTERACTION BETWEEN MDM2 AND P53 JANSSEN PHARMACEUTICA NV (BE) 2017-04-27 US disclosed
US-20170112818-A1 INHIBITORS OF THE INTERACTION BETWEEN MDM2 AND P53 JANSSEN PHARMACEUTICA NV (BE) 2017-04-27 US disclosed
US-9573933-B2 Inhibitors of the interaction between MDM2 and P53 JANSSEN PHARMACEUTICA NV (BE) 2017-02-21 US disclosed
US-9573933-B2 Inhibitors of the interaction between MDM2 and P53 JANSSEN PHARMACEUTICA NV (BE) 2017-02-21 US disclosed
US-20100240637-A1 Inhibitors of the Interaction Between MDM2 and P53 JANSSEN PHARMACEUTICAL NV (BE) 2010-09-23 US disclosed
US-20100240637-A1 Inhibitors of the Interaction Between MDM2 and P53 JANSSEN PHARMACEUTICAL NV (BE) 2010-09-23 US disclosed
WO-2009037308-A1 INHIBITORS OF THE INTERACTION BETWEEN MDM2 AND P53 JANSSEN PHARMACEUTICA NV (BE) 2009-03-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100240637-A1 Inhibitors of the Interaction Between MDM2 and P53 TP53, MDM2, TP53BP1 GAK 947/4885RIPK2 741/4885COQ8A 2374/4885
US-20170112818-A1 INHIBITORS OF THE INTERACTION BETWEEN MDM2 AND P53 TP53, MDM2, TP53BP1 GAK 947/4885RIPK2 741/4885COQ8A 2374/4885
US-11583524-B2 Inhibitors of the interaction between MDM2 and P53 TP53, MDM2, TP53BP1 GAK 947/4885RIPK2 741/4885COQ8A 2374/4885
US-20200121667-A1 Inhibitors Of The Interaction Between MDM2 And P53 TP53, MDM2, TP53BP1 GAK 966/4885RIPK2 829/4885COQ8A 2408/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.